Navigation Links
Milestone Scientific to Exhibit at the DPRWorld(TM) 08 in Las Vegas, Nevada

LIVINGSTON, N.J., May 14 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that it will be showcasing and demonstrating its award winning STA(TM) System at the upcoming DPRWorld 08 (Dental Products Report) in Las Vegas, Nevada.

WHEN: Thursday, May 15 - Saturday, May 17, 2008

WHERE: Booth #262

Mandalay Bay

3950 Las Vegas Blvd. SouthLas Vegas, Nevada 89119

WHO: Bob Presutti, Vice President of Sales & Marketing, Milestone


Other Sales Representatives from Milestone Scientific

WHAT: Demonstrations of the STA System

-- According to a December 2007 article published in Contemporary

Dental Assistant magazine, "The (STA) instrument is highly

effective in all areas of the oral cavity, including those

areas of dense connective tissue, such as the hard palate.

Dentists can provide traditional block anesthesia and

infiltration injections with this technology; however, special

techniques also may be employed to provide local anesthesia to

the precise teeth targeted for treatment via the periodontal

ligament (PDL) injection. The routine side effects of facial

and lingual numbness from a traditional anesthetic injection

soon may be a thing of the past."

-- Learn first hand how Milestone is redefining the standard of

care of the delivery of local anesthesia in dentistry.

-- Discover how the STA System is improving patient care and the

dental practice efficiency for those dentists who have adopted

CCLAD (Computer Controlled Local Anesthesia Delivery)

technology to more comfortably administer all dental

injections performed in their dental operatories.

NOTE TO PRESS: To arrange one-on-one interviews with Mr. Presutti, or to schedule a personal demonstration of the STA System, please contact John Morrison or Tiffany Korkis, Directors, Elite Media Group, at 407-585-1080 or via email at

About DPRWorld

DPRWorld is a dynamic, completely new type of dental event -- a forum that enables forward-thinking dentists to reap the benefits of the latest industry advances in a setting that encourages communication and commerce. Uniquely focused on innovation, DPRWorld will deliver a sophisticated, interactive showcase of leading-edge products, equipment and technology, and world-class education. Here, in an environment created by America's leading dental publications, you will find everything you need to stay current and further develop your practice. A custom educational experience will empower you to become a better-educated consumer of the products and services you need to make your practice efficient and profitable.

About Milestone Scientific Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(R) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The STA(TM) (Single Tooth Anesthesia) System computer- controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2007. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.


Elite Financial Communications Group, LLC

Dodi Handy, President and CEO

407-585-1080 or via email at

SOURCE Milestone Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
3. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
4. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
5. Smurfit-Stones Hodge, LA, Mill Becomes First to Achieve Safety Milestone
6. Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization
7. Milestone Scientific to Present at the Edgewater Research Investor Conference
8. Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
9. Global Gene Map Clears New Milestone
10. Free Site Offering Patient-Physician Dialog Reaches Milestone
11. Marlo Thomas and St. Jude Childrens Research Hospital(R) Announce Hitting The 50-Partner Milestone as They Kick Off the Fourth Annual Thanks and Giving(R) Campaign Which Asks America to Support St. Jude While Shopping This Holiday Season
Post Your Comments:
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... ... 27, 2015 , ... Consistent with the Radiology Business ... Better Radiology Marketing Programs meeting will showcase some of the best 2015 ... Caesars Palace in Las Vegas with a pre-conference session on a collaborative approach ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 --> ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... found that immunotherapy can be efficiently combined with photodynamic ...
(Date:11/26/2015)... SAN FRANCISCO , November 26, 2015 ... 1.82 billion by 2022, according to a new report by ... as Chronic Kidney Disease (CKD) which demands kidney transplantation is ... convenient and cost effective substitute for organ transplantation. --> ... 1.82 billion by 2022, according to a new report by ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology: